DS
DSRLF.US DiaSorin S.p.A
- Market cap
- USD 4.53B
- P/E
- 29.0x
- P/B
- 2.85x
- ROE
- 17.1%
- Dividend yield
- 1.64%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DSRLF.US undervalued?
Graham numberDSRLF.US trades 91.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DiaSorin S.p.A fundamental analysis
No fundamental analysis for DiaSorin S.p.A yet.
DiaSorin S.p.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DiaSorin S.p.A
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV…
Full company profileDiaSorin S.p.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DiaSorin S.p.A annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 569M | 637M | 669M | 706M | 881M | 1.24B | 1.36B | 1.15B | 1.19B | 1.19B | 1.78B |
| Gross Profit | 389M | 432M | 456M | 489M | 603M | 825M | 901M | 741M | 782M | 773M | 1.15B |
| Operating Income | 173M | 184M | 205M | 218M | 324M | 419M | 351M | 216M | 258M | 270M | 382M |
| EBITDA | 217M | 237M | 258M | 279M | 386M | 517M | 514M | 347M | 399M | 364M | 532M |
| Net Income | 112M | 140M | 158M | 176M | 248M | 311M | 241M | 160M | 188M | 156M | 244M |
| EPS | 2.04 | 2.54 | 2.85 | 3.20 | 4.50 | 5.40 | 4.15 | 2.87 | 3.37 | 2.78 | 4.36 |
| Balance Sheet | |||||||||||
| Total Assets | 869M | 946M | 906M | 1.06B | 1.25B | 3.23B | 3.41B | 3.21B | 3.30B | 2.87B | 2.90B |
| Total Liabilities | 205M | 204M | 201M | 215M | 290M | 1.86B | 1.89B | 1.67B | 1.51B | 1.30B | 1.48B |
| Shareholders' Equity | 663M | 741M | 705M | 849M | 955M | 1.37B | 1.52B | 1.54B | 1.80B | 1.58B | 1.42B |
| Cash & Short-term Investments | 130M | 173M | 96.5M | 202M | 340M | 403M | 413M | 379M | 344M | 208M | 121M |
| Total Debt | 50.4M | 24.0M | 20.7M | 29.3M | 34.7M | 1.40B | 1.35B | 1.19B | 1.01B | 791M | 959M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 166M | 167M | 210M | 233M | 305M | 401M | 389M | 312M | 359M | 343M | 334M |
| Capital Expenditure | 37.4M | 42.5M | 52.8M | 55.8M | 74.8M | 117M | 114M | 45.5M | 120M | 138M | 66.0M |
| Free Cash Flow | 128M | 125M | 157M | 177M | 230M | 283M | 276M | 266M | 239M | 205M | 268M |
| Ratios | |||||||||||
| ROE | 17.0% | 18.9% | 22.4% | 20.7% | 26.0% | 22.8% | 15.9% | 10.4% | 10.4% | 9.8% | 17.1% |
| ROA | 12.9% | 14.8% | 17.5% | 16.5% | 19.9% | 9.6% | 7.1% | 5.0% | 5.7% | 5.4% | 8.4% |
| Net Profit Margin | 19.7% | 21.9% | 23.6% | 24.9% | 28.1% | 25.1% | 17.7% | 13.9% | 15.9% | 13.0% | 13.7% |
| Debt to Equity | 0.08x | 0.03x | 0.03x | 0.03x | 0.04x | 1.02x | 0.89x | 0.78x | 0.56x | 0.50x | 0.67x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DiaSorin S.p.A dividends
- Dividend yield
- 1.64%
- Forward dividend
- 1.51 USD
- Payout ratio
- 40.8%
- Ex-dividend date
- May 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 63.5M | 1.14 | 40.8% |
| 2024 | EUR 61.3M | 1.10 | 32.6% |
| 2023 | EUR 59.0M | 1.06 | 36.9% |
| 2022 | USD 57.1M | 0.98 | 23.7% |
| 2021 | USD 54.7M | 0.95 | 17.6% |
| 2020 | USD 52.1M | 0.95 | 21.0% |
| 2019 | USD 49.2M | 0.90 | 28.0% |
| 2018 | USD 145M | 2.62 | 91.9% |
| 2017 | USD 43.8M | 0.80 | 31.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns DiaSorin S.p.A
- Insiders 57.56%
- Institutions 14.27%
- Public & others 28.17%
- Shares outstanding 49.3M
- Free float 14.9M
DiaSorin S.p.A company profile
- Company name
- DiaSorin S.p.A
- Ticker
- DSRLF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,212
- Fiscal year end
- December
- Address
- Via Crescentino snc, Saluggia, VC, Italy, 13040
- Phone
- 39 016 1487526
- Website
- int.diasorin.com
About DiaSorin S.p.A
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
DiaSorin S.p.A management
10- Mr. Carlo RosaCEO, GM & Executive Director · born 1966
- Dr. Chen Menachem EvenChief Commercial Officer, Senior Corporate VP of Commercial Operations & Executive Director · born 1963
- Mr. Alberto DonatiChief Financial Officer · born 1987
- Mr. Fabrizio Piercarlo BonelliChief Scientific Officer
- Ms. Margherita SacerdotiInvestor Relations & ESG Senior Director · born 1983
- Mr. Ulisse SpadaCorporate VP, Head of the Legal Department, Secretary & General Counsel
- Ms. Amelia ParenteSenior Corporate Vice President of Human Resources
- Mr. Alberto CampaniCEO, GM of Diasorin Italy & VP of Global Immuno Operations
- Mr. Luigi CiccheseSenior Corporate VP of Systems & Engineering
- Ms. Rita MaffeiSenior Corporate VP of Quality, Regulatory & Clinical Affairs